David Wang

Director, Centre for Technology and Development


David Wang is the Director of Centre of Technology Development at Duke-NUS. David has years of experiences in intellectual property management, technology acceleration and commercialization, and new ventures. From 2017 to 2020 David was a Senior Acceleration Manager at Innovation Ventures of Cincinnati Children’s, an international leader in pediatric medicine, research and education. He led the assessment, identification, acceleration management of Cincinnati Children’s most promising biomedical programs, resulting in translational value creation and closure of massive transactions in licensing, product co-development, and venture investment. Prior to joining Cincinnati Children’s, David founded a life science company and secured $6 million venture funding for the company. As the company founder, he managed whole cycle of product development and translated pioneering concepts into FDA-approved proprietary products. Previously, David worked for a number of years as a senior innovation manager at Cleveland Clinic, as a license manager at the University of Rochester, and as a drug discovery scientist at Pfizer. David received Bachelor (MBBS) and Master of Medicine from Hunan Medical University in China, and MBA from the University of Michigan. David has catalyzed the translation of innovations into real world solutions for unmet biomedical needs, led and provided expert advising and coaching to innovators over the total product life cycle, created start-up ventures, raised first seed capital, and led to rounds of venture capital and corporate partnerships. David has negotiated and completed numerous transactions in licenses, options, product co-development, and seed/venture investments. David received 2020 Educational Institution and Federal Laboratory Partnership Award for his outstanding works in technology transfer and management of collaboration between Cincinnati Children’s and NIH. David secured Certified Licensing Professional (CLP) designation in 2021.